In connection with the Rights Issue, a total of 31,199,997 new shares, each at a subscription price of NOK 0.50 (the "Underwriting Commission Shares") shall be delivered to the underwriters pursuant to the subscription and underwriting agreements dated 30 June 2025 as settlement of their entitlement to underwriting fee under said agreements.

In accordance with the authorisation granted to the board of directors at the extraordinary general meeting held on 4 August 2025, the board of directors has today resolved to increase the share capital of the Company by NOK 15,599,998.50 by the issuance of 31,199,997 new shares, each with a nominal value of NOK 0.5 and a subscription price of NOK 0.50. The subscription price of NOK 0.50 per Underwriting Commission Share is equal to the subscription price in the Rights Issue.

The share capital increase relating to the issuance of the Underwriting Commission Shares is expected to be registered with the Norwegian Register of Business Enterprises on or about 9 December 2025, and the Underwriting Commission Shares are expected to be delivered to the underwriters on or about 10 December 2025.

For further information, please contact:

Oystein Soug, Chief Executive Officer

Email: soug@oncoinvent.com

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. 

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases in the peritoneum post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. One Phase 1 trial and one Phase 1/2a trial have been completed and one randomized Phase 2 trial in ovarian cancer is currently ongoing in the US and Europe. Early clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. Oncoinvent runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Oslo Stock Exchange.

About Radspherin®

Radspherin® is an innovative internal radiation therapy designed to directly target microscopic metastases in the abdominal cavity following surgery. Radspherin® is currently in development as a post-surgical treatment for patients with cancer that has spread to the abdominal cavity - a group with very limited treatment options today. The drug candidate offers a distinctly unique therapeutic approach with several differentiating features, including the use of radium-224, single-dose treatment with a sustained therapeutic effect, non-systemic administration, direct targeting and an exceptional dose-to-tumor ratio, maximizing efficacy while limiting harm to healthy tissue